| Autor: |
Moriwaki T; Dept. of Internal Medicine, National Hospital Organization Shikoku Cancer Center., Hyodo I, Nishina T, Kajiwara T, Kataoka J, Hori S, Nasu J, Imamine S, Iguchi H |
| Jazyk: |
japonština |
| Zdroj: |
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2007 Dec; Vol. 34 (13), pp. 2249-53. |
| Abstrakt: |
The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively. 20 patients were treated with FOLFIRI at our hospital between October 2003 and November 2005. The objective overall response rate was 28% (5/18; 95% confidence interval, 9.7-54%). The disease control rate (CR+PR+SD) was 61%. The most frequent grade 3 to 4 adverse event was neutropenia, and it was seen in 50%. Non-hematological toxicities were mild. The median survival time was 11 months. The 1-year survival rate was 34%. This study showed the activity and safety of FOLFIRI in practice. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
